Tumor-specific synthetic antigen (TSSA)

Tumor-specific synthetic antigens are engineered molecules, typically peptides or nucleic acids, designed to mimic unique epitopes found exclusively or predominantly on malignant cells. These antigens are central to the development of personalized cancer vaccines and advanced immunotherapies, where they serve as the blueprint for the immune system to identify and eliminate cancer cells while sparing healthy tissue. By utilizing genomic sequencing of a patient's tumor, researchers can identify somatic mutations and synthesize corresponding neoantigens that are highly immunogenic. (Source: Nature Reviews Cancer, 2021; NIH National Cancer Institute). In clinical applications, these synthetic antigens are often delivered via mRNA, DNA, or peptide platforms to stimulate a robust T-cell response. Their primary biological role is to enhance the visibility of the tumor to the host's immune system, overcoming the immunosuppressive environment often found in the tumor microenvironment. Because these antigens are synthetic and tailored to specific mutations, they offer a high degree of specificity, reducing the risk of cross-reactivity with self-antigens found on normal cells. (Source: Frontiers in Immunology, 2022; PubMed PMC7355124).

Other names

Synthetic neoantigenSynthetic tumor-associated antigenSynthetic long peptide (SLP)Designer antigenCustomized tumor antigen

Induction of a de novo or amplified T-cell mediated immune response by presenting synthetic sequences that mimic tumor-specific mutations (neoantigens) or overexpressed proteins via MHC molecules to activate CD4+ and CD8+ T cells.